Patricia A. Deverka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patricia A. Deverka has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Kathryn A. Phillips
Kathryn A. Phillips, University of California San Francisco
1 shared publicationMichael P. Douglas
Michael P. Douglas, University of California San Francisco
1 shared publication
Latest Publications
- 1 March 2022
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 41 (3) , 383-389
Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access
There is a tremendous public health need to identify potentially lethal cancers at earlier stages, when there is a greater chance for improved survival. Although in the US there are currently screening recommendations for only five cancers (breast, colorectal, cervical, lung, and prostate), new tests can screen for up to fifty cancers simultaneously based on a simple blood draw. However, these multicancer screening tests (also called “liquid biopsy” tests) will also present challenges to payers because of intrinsic features of the tests and the complexity of payer coverage assessments for screening tests. We describe these considerations while also offering potential solutions that can inform payers’ decision making if these tests prove to be beneficial.
- 1 March 2022
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 41 (3) , 383-389
Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access
There is a tremendous public health need to identify potentially lethal cancers at earlier stages, when there is a greater chance for improved survival. Although in the US there are currently screening recommendations for only five cancers (breast, colorectal, cervical, lung, and prostate), new tests can screen for up to fifty cancers simultaneously based on a simple blood draw. However, these multicancer screening tests (also called “liquid biopsy” tests) will also present challenges to payers because of intrinsic features of the tests and the complexity of payer coverage assessments for screening tests. We describe these considerations while also offering potential solutions that can inform payers’ decision making if these tests prove to be beneficial.